by | May 15, 2024 | Publications
Clin Exp Immunol. 2024 May 14:uxae043. doi: 10.1093/cei/uxae043. Online ahead of print. ABSTRACT Serum B-cell maturation antigen (sBCMA) levels can serve as a sensitive biomarker in multiple myeloma (MM). In the research setting, sBCMA levels can be accurately...
by | May 14, 2024 | Publications
J Neuroophthalmol. 2024 Jun 1;44(2):e244-e245. doi: 10.1097/WNO.0000000000001793. Epub 2023 Jan 4. NO ABSTRACT PMID:38741250 | DOI:10.1097/WNO.0000000000001793
by | May 14, 2024 | Publications
Nephrology (Carlton). 2024 May 14. doi: 10.1111/nep.14315. Online ahead of print. ABSTRACT This case report describes a rare and interesting case of a patient with multiple myeloma complicated with light chain (LC) cast nephropathy and focal amyloidosis. The patient...
by | May 13, 2024 | Publications
Blood Adv. 2024 May 13:bloodadvances.2023012539. doi: 10.1182/bloodadvances.2023012539. Online ahead of print. ABSTRACT In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard of care regimens. In a...
by | May 13, 2024 | Publications
MedComm (2020). 2024 May 9;5(5):e562. doi: 10.1002/mco2.562. eCollection 2024 May. ABSTRACT The proteasome inhibitor bortezomib (BTZ) is the first-line therapy for multiple myeloma (MM). BTZ resistance largely limits its clinical application in MM. Interleukin-33...
by | May 13, 2024 | Publications
Cureus. 2024 Apr 11;16(4):e58066. doi: 10.7759/cureus.58066. eCollection 2024 Apr. ABSTRACT Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow, often leading to various end-organ damages. Here, we...
